IBDEI36O ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,50830,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50830,1,3,0)
;;=3^Personal Hx of Leukemia
;;^UTILITY(U,$J,358.3,50830,1,4,0)
;;=4^Z85.6
;;^UTILITY(U,$J,358.3,50830,2)
;;=^5063434
;;^UTILITY(U,$J,358.3,50831,0)
;;=Z85.72^^193^2498^98
;;^UTILITY(U,$J,358.3,50831,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50831,1,3,0)
;;=3^Personal Hx of Non-Hodgkin Lymphomas
;;^UTILITY(U,$J,358.3,50831,1,4,0)
;;=4^Z85.72
;;^UTILITY(U,$J,358.3,50831,2)
;;=^5063436
;;^UTILITY(U,$J,358.3,50832,0)
;;=Z85.79^^193^2498^88
;;^UTILITY(U,$J,358.3,50832,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50832,1,3,0)
;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
;;^UTILITY(U,$J,358.3,50832,1,4,0)
;;=4^Z85.79
;;^UTILITY(U,$J,358.3,50832,2)
;;=^5063437
;;^UTILITY(U,$J,358.3,50833,0)
;;=Z85.820^^193^2498^77
;;^UTILITY(U,$J,358.3,50833,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50833,1,3,0)
;;=3^Personal Hx of Malig Melanoma of Skin
;;^UTILITY(U,$J,358.3,50833,1,4,0)
;;=4^Z85.820
;;^UTILITY(U,$J,358.3,50833,2)
;;=^5063441
;;^UTILITY(U,$J,358.3,50834,0)
;;=Z85.828^^193^2498^92
;;^UTILITY(U,$J,358.3,50834,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50834,1,3,0)
;;=3^Personal Hx of Malig Neop of Skin
;;^UTILITY(U,$J,358.3,50834,1,4,0)
;;=4^Z85.828
;;^UTILITY(U,$J,358.3,50834,2)
;;=^5063443
;;^UTILITY(U,$J,358.3,50835,0)
;;=Z85.71^^193^2498^72
;;^UTILITY(U,$J,358.3,50835,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50835,1,3,0)
;;=3^Personal Hx of Hodgkin Lymphoma
;;^UTILITY(U,$J,358.3,50835,1,4,0)
;;=4^Z85.71
;;^UTILITY(U,$J,358.3,50835,2)
;;=^5063435
;;^UTILITY(U,$J,358.3,50836,0)
;;=Z65.8^^193^2498^144
;;^UTILITY(U,$J,358.3,50836,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50836,1,3,0)
;;=3^Psychosocial Circumstance Related Problems
;;^UTILITY(U,$J,358.3,50836,1,4,0)
;;=4^Z65.8
;;^UTILITY(U,$J,358.3,50836,2)
;;=^5063185
;;^UTILITY(U,$J,358.3,50837,0)
;;=Z86.11^^193^2498^109
;;^UTILITY(U,$J,358.3,50837,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50837,1,3,0)
;;=3^Personal Hx of Tuberculosis
;;^UTILITY(U,$J,358.3,50837,1,4,0)
;;=4^Z86.11
;;^UTILITY(U,$J,358.3,50837,2)
;;=^5063461
;;^UTILITY(U,$J,358.3,50838,0)
;;=Z86.13^^193^2498^76
;;^UTILITY(U,$J,358.3,50838,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50838,1,3,0)
;;=3^Personal Hx of Malaria
;;^UTILITY(U,$J,358.3,50838,1,4,0)
;;=4^Z86.13
;;^UTILITY(U,$J,358.3,50838,2)
;;=^5063463
;;^UTILITY(U,$J,358.3,50839,0)
;;=Z86.73^^193^2498^106
;;^UTILITY(U,$J,358.3,50839,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50839,1,3,0)
;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
;;^UTILITY(U,$J,358.3,50839,1,4,0)
;;=4^Z86.73
;;^UTILITY(U,$J,358.3,50839,2)
;;=^5063477
;;^UTILITY(U,$J,358.3,50840,0)
;;=Z86.79^^193^2498^69
;;^UTILITY(U,$J,358.3,50840,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50840,1,3,0)
;;=3^Personal Hx of Circulatory System Diseases
;;^UTILITY(U,$J,358.3,50840,1,4,0)
;;=4^Z86.79
;;^UTILITY(U,$J,358.3,50840,2)
;;=^5063479
;;^UTILITY(U,$J,358.3,50841,0)
;;=Z91.040^^193^2498^57
;;^UTILITY(U,$J,358.3,50841,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50841,1,3,0)
;;=3^Latex Allergy Status
;;^UTILITY(U,$J,358.3,50841,1,4,0)
;;=4^Z91.040
;;^UTILITY(U,$J,358.3,50841,2)
;;=^5063607
;;^UTILITY(U,$J,358.3,50842,0)
;;=Z92.3^^193^2498^73
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI36O 3749 printed Sep 23, 2025@20:18:52 Page 2
IBDEI36O ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,50830,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,50830,1,3,0)
+4 ;;=3^Personal Hx of Leukemia
+5 ;;^UTILITY(U,$J,358.3,50830,1,4,0)
+6 ;;=4^Z85.6
+7 ;;^UTILITY(U,$J,358.3,50830,2)
+8 ;;=^5063434
+9 ;;^UTILITY(U,$J,358.3,50831,0)
+10 ;;=Z85.72^^193^2498^98
+11 ;;^UTILITY(U,$J,358.3,50831,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,50831,1,3,0)
+14 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
+15 ;;^UTILITY(U,$J,358.3,50831,1,4,0)
+16 ;;=4^Z85.72
+17 ;;^UTILITY(U,$J,358.3,50831,2)
+18 ;;=^5063436
+19 ;;^UTILITY(U,$J,358.3,50832,0)
+20 ;;=Z85.79^^193^2498^88
+21 ;;^UTILITY(U,$J,358.3,50832,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,50832,1,3,0)
+24 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
+25 ;;^UTILITY(U,$J,358.3,50832,1,4,0)
+26 ;;=4^Z85.79
+27 ;;^UTILITY(U,$J,358.3,50832,2)
+28 ;;=^5063437
+29 ;;^UTILITY(U,$J,358.3,50833,0)
+30 ;;=Z85.820^^193^2498^77
+31 ;;^UTILITY(U,$J,358.3,50833,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,50833,1,3,0)
+34 ;;=3^Personal Hx of Malig Melanoma of Skin
+35 ;;^UTILITY(U,$J,358.3,50833,1,4,0)
+36 ;;=4^Z85.820
+37 ;;^UTILITY(U,$J,358.3,50833,2)
+38 ;;=^5063441
+39 ;;^UTILITY(U,$J,358.3,50834,0)
+40 ;;=Z85.828^^193^2498^92
+41 ;;^UTILITY(U,$J,358.3,50834,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,50834,1,3,0)
+44 ;;=3^Personal Hx of Malig Neop of Skin
+45 ;;^UTILITY(U,$J,358.3,50834,1,4,0)
+46 ;;=4^Z85.828
+47 ;;^UTILITY(U,$J,358.3,50834,2)
+48 ;;=^5063443
+49 ;;^UTILITY(U,$J,358.3,50835,0)
+50 ;;=Z85.71^^193^2498^72
+51 ;;^UTILITY(U,$J,358.3,50835,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,50835,1,3,0)
+54 ;;=3^Personal Hx of Hodgkin Lymphoma
+55 ;;^UTILITY(U,$J,358.3,50835,1,4,0)
+56 ;;=4^Z85.71
+57 ;;^UTILITY(U,$J,358.3,50835,2)
+58 ;;=^5063435
+59 ;;^UTILITY(U,$J,358.3,50836,0)
+60 ;;=Z65.8^^193^2498^144
+61 ;;^UTILITY(U,$J,358.3,50836,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,50836,1,3,0)
+64 ;;=3^Psychosocial Circumstance Related Problems
+65 ;;^UTILITY(U,$J,358.3,50836,1,4,0)
+66 ;;=4^Z65.8
+67 ;;^UTILITY(U,$J,358.3,50836,2)
+68 ;;=^5063185
+69 ;;^UTILITY(U,$J,358.3,50837,0)
+70 ;;=Z86.11^^193^2498^109
+71 ;;^UTILITY(U,$J,358.3,50837,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,50837,1,3,0)
+74 ;;=3^Personal Hx of Tuberculosis
+75 ;;^UTILITY(U,$J,358.3,50837,1,4,0)
+76 ;;=4^Z86.11
+77 ;;^UTILITY(U,$J,358.3,50837,2)
+78 ;;=^5063461
+79 ;;^UTILITY(U,$J,358.3,50838,0)
+80 ;;=Z86.13^^193^2498^76
+81 ;;^UTILITY(U,$J,358.3,50838,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,50838,1,3,0)
+84 ;;=3^Personal Hx of Malaria
+85 ;;^UTILITY(U,$J,358.3,50838,1,4,0)
+86 ;;=4^Z86.13
+87 ;;^UTILITY(U,$J,358.3,50838,2)
+88 ;;=^5063463
+89 ;;^UTILITY(U,$J,358.3,50839,0)
+90 ;;=Z86.73^^193^2498^106
+91 ;;^UTILITY(U,$J,358.3,50839,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,50839,1,3,0)
+94 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
+95 ;;^UTILITY(U,$J,358.3,50839,1,4,0)
+96 ;;=4^Z86.73
+97 ;;^UTILITY(U,$J,358.3,50839,2)
+98 ;;=^5063477
+99 ;;^UTILITY(U,$J,358.3,50840,0)
+100 ;;=Z86.79^^193^2498^69
+101 ;;^UTILITY(U,$J,358.3,50840,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,50840,1,3,0)
+104 ;;=3^Personal Hx of Circulatory System Diseases
+105 ;;^UTILITY(U,$J,358.3,50840,1,4,0)
+106 ;;=4^Z86.79
+107 ;;^UTILITY(U,$J,358.3,50840,2)
+108 ;;=^5063479
+109 ;;^UTILITY(U,$J,358.3,50841,0)
+110 ;;=Z91.040^^193^2498^57
+111 ;;^UTILITY(U,$J,358.3,50841,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,50841,1,3,0)
+114 ;;=3^Latex Allergy Status
+115 ;;^UTILITY(U,$J,358.3,50841,1,4,0)
+116 ;;=4^Z91.040
+117 ;;^UTILITY(U,$J,358.3,50841,2)
+118 ;;=^5063607
+119 ;;^UTILITY(U,$J,358.3,50842,0)
+120 ;;=Z92.3^^193^2498^73
